Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 7:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Product B Clear all
Active, not recruiting Phase 2 Interventional

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

NCT03712202
View directory record Official record
Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
Interventions
Bleomycin, Brentuximab Vedotin, Dacarbazine, Doxorubicin, Nivolumab, Quality-of-Life Assessment, Vinblastine
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional Results available

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

NCT01525628
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 22, 2026, 7:58 PM EDT
Terminated Phase 1Phase 2 Interventional

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

NCT05162365
View directory record Official record
Conditions
COVID-19
Interventions
IBI314, Placebo
Biological · Other
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
19
States / cities
Anaheim, California • Long Beach, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

NCT04268771
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®
Biological
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Palmdale, California • Upland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

NCT04890873
View directory record Official record
Conditions
Obesity
Interventions
ERX1000, Placebo
Drug
Lead sponsor
ERX Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 22, 2026, 7:58 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 2 Interventional Results available

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

NCT01903031
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Nuvaring, EFV, ATV/r, TDF, NRTIs
Device · Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

NCT02807675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

NCT05845645
View directory record Official record
Conditions
Healthy Study Participants
Interventions
UCB0599, Esomeprazole, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

NCT03111992
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PDR001, CJM112, LCL161
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Phoenix, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

NCT00853736
View directory record Official record
Conditions
Healthy
Interventions
Roxicodone™ tablet 30 mg, Oxycodone hydrochloride tablet 30 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation

NCT00629122
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Tacrolimus (Arm B), Clotrimazole Troche, Tacrolimus (Arm A), Nystatin Suspension
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 22, 2026, 7:58 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

NCT00707239
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
tigecycline, imipenem/cilastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 2 Interventional Results available

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830
View directory record Official record
Conditions
Cancer
Interventions
Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants

NCT04515628
View directory record Official record
Conditions
Healthy Participants
Interventions
Rosuvastatin, Branebrutinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults

NCT01779505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GS-4774
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

NCT01231594
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, GSK1120212, Other approved anti-cancer agent
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
25
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 2 Interventional

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

NCT00201747
View directory record Official record
Conditions
Esophageal Cancer, Esophagus Cancer, Cancer of Stomach, Stomach Cancer
Interventions
CPT-11, Mitomycin C
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contact Lenses

NCT01583868
View directory record Official record
Conditions
Myopia
Interventions
B&L RD2135-01 lens C, B&L RD2135-01 lens D, PureVision2, Air Optix Aqua
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 22, 2026, 7:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat Tablets in Healthy Adults

NCT05284760
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 22, 2026, 7:58 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation

NCT03420313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone sublingual tablets
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 22, 2026, 7:58 PM EDT
Terminated Phase 1 Interventional

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

NCT04982224
View directory record Official record
Conditions
Advanced NSCLC
Interventions
REGN5093-M114, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Orange, California • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 22, 2026, 7:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

NCT06384261
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cusatuzumab, Venetoclax, Azacitidine
Drug
Lead sponsor
OncoVerity, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 22, 2026, 7:58 PM EDT